학술논문

A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma
Document Type
Journal
Source
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY; JUL 1 2022, 13p.
Subject
Language
English
ISSN
14321335